Skip to content

house · Committee report

H. Rept. 119-724

STEM CELL THERAPEUTIC AND RESEARCH REAUTHORIZATION ACT OF 2025

2026-07-02

Committees

Associated legislation

Text

Purpose and Summary

H.R. 5160, introduced on September 4, 2025, by Representatives Chris Smith (R-NJ) and Doris Matsui (D-CA), reauthorizes the C.W. Bill Young Cell Transplantation program and the National Cord Blood Inventory program through Fiscal Year 2031.

Background and Need for Legislation

In the United States, approximately 18,500 patients are diagnosed with a life-threatening blood cancer or other diseases that necessitate a blood stem cell transplant each year. Only one quarter of individuals who are seeking a transplant will be matched with a family member; the remaining individuals must receive a transplant from a biologically unrelated donor or umbilical cord blood unit (CBU).\1\ The C.W. Bill Young Cell Transplantation program (CWBYCTP) supports the process of identifying, matching, and facilitating the distribution of bone marrow, peripheral blood stem cells, and cord blood from biologically unrelated donors for patients who necessitate blood stem cell transplants.\2\ --------------------------------------------------------------------------- \1\Health Resources & Services Administration, Report to Congress, Fiscal Year 2024 Annual Progress Report on the C.W. Bill Young Cell Transplantation Program and National Cord Blood Inventory Program, (2024), https://bloodstemcell.hrsa.gov/sites/default/files/ bloodstemcell/about/legislation/fiscal-year-2024-annual-progress- report.pdf. \2\Id. --------------------------------------------------------------------------- In 2005, the Stem Cell Therapeutic and Research Act was signed into law, creating the C.W. Bill Young Cell Transplantation Program to replace the National Bone Marrow Donor Registry (NBMDR), established in 1987 through a Congressionally-directed grant from the U.S. Department of the Navy.\3\ This law directed the Secretary of HHS to collect and store 150,000 units of ``high-quality and genetically diverse cord blood'' for transplantation.\4\ It authorized contracting with cord blood banks and created the National Cord Blood Inventory (NCBI) to support and coordinate banking efforts.\5\ This program was amended and reauthorized in 2010, 2015, and 2021.\6\ --------------------------------------------------------------------------- \3\Stem Cell Therapeutic and Research Act of 2005, Pub. L. No. 109- 129, 119 Stat. 2005; see also Health Resources & Services Administration, Legislation (Feb. 2026), https:// bloodstemcell.hrsa.gov/about/legislation. \4\Government Accountability Office (GAO), National Cord Blood Inventory: Practices for Increasing Availability for Transplants and Related Challenges, GAO-12-23 at page 1 (Oct. 2011), https:// www.gao.gov/assets/gao-12-23.pdf. \5\GAO, supra note 4. \6\Health Resources & Services Administration, Legislation (Feb. 2026), https://bloodstemcell.hrsa.gov/about/legislation. --------------------------------------------------------------------------- H.R. 5160, the Stem Cell Therapeutic and Research Reauthorization Act of 2025, reauthorizes the C.W. Bill Young Cell Transplantation program and the National Cord Blood Inventory program through Fiscal Year 2031. Additionally, this bill updates certain provisions to reflect current evidence- based scientific and clinical practices.

Committee Action

On April 15, 2026, the Subcommittee on Health held a legislative hearing on H.R. 5160. The title of the hearing was ``Healthier America: Legislative Proposals to Improve Public Health.'' The Subcommittee received testimony from: Jamie Ulmer, MA, President and CEO, Healthcare Network Rachel F. Brem, MD, FACR, FSBI, Co-Founder, Chief Medical Officer, Brem Foundation to Defeat Breast Cancer and Professor and Vice-Chair Emeritus, The George Washington University Holly Ahern, MS, MT(ASCP), Associate Professor of Microbiology, State University of New York Adirondack Amy L. Ronneberg, MBA, Chief Executive Officer, National Marrow Donor Program Brian Wallach & Sandra Abrevaya, Co- Founders, I AM ALS Rene Quashie, JD, Vice President, Digital Health, Consumer Technology Association On May 13, 2026, the Subcommittee on Health met in open markup session and forwarded H.R. 5160, without amendment, to the full Committee by a voice vote. On May 21, 2026, the full Committee on Energy and Commerce met in open markup session and ordered H.R. 5160, as amended, favorably reported to the House by a record vote of 46 yeas and 0 nays.

Committee Votes

Clause 3(b) of rule XIII requires the Committee to list the record votes on the motion to report legislation and amendments thereto. The following reflects the record votes taken during the Committee consideration: [GRAPHIC(S) NOT AVAILABLE IN TIFF FORMAT] Oversight Findings and Recommendations Pursuant to clause 2(b)(1) of rule X and clause 3(c)(1) of rule XIII, the Committee held hearings and made findings that are reflected in this report. New Budget Authority, Entitlement Authority, and Tax Expenditures Pursuant to clause 3(c)(2) of rule XIII, the Committee finds that H.R. 5160 would result in no new or increased budget authority, entitlement authority, or tax expenditures or revenues.

Congressional Budget Office Estimate

Pursuant to clause 3(c)(3) of rule XIII, at the time this report was filed, the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974 was not available. Federal Mandates Statement The Committee adopts as its own the estimate of Federal mandates prepared by the Director of the Congressional Budget Office pursuant to section 423 of the Unfunded Mandates Reform Act. Statement of General Performance Goals and Objectives Pursuant to clause 3(c)(4) of rule XIII, the general performance goal or objective of this legislation is to reauthorize the C.W. Bill Young Cell Transplantation program and the National Cord Blood Inventory program through Fiscal Year 2031. Duplication of Federal Programs Pursuant to clause 3(c)(5) of rule XIII, no provision of H.R. 5160 is known to be duplicative of another Federal program, including any program that was included in a report to Congress pursuant to section 21 of Public Law 111-139 or the most recent Catalog of Federal Domestic Assistance. Related Committee and Subcommittee Hearings Pursuant to clause 3(c)(6) of rule XIII, the following related hearings were used to develop or consider H.R. 5160: On April 15, 2026, the Subcommittee on Health held a legislative hearing on H.R. 5160. The title of the hearing was ``Healthier America: Legislative Proposals to Improve Public Health.'' The Subcommittee received testimony from: Jamie Ulmer, MA, President and CEO, Healthcare Network; Rachel F. Brem, MD, FACR, FSBI, Co-Founder, Chief Medical Officer, Brem Foundation to Defeat Breast Cancer and Professor and Vice-Chair Emeritus, The George Washington University; Holly Ahern, MS, MT(ASCP), Associate Professor of Microbiology, State University of New York Adirondack; Amy L. Ronneberg, MBA, Chief Executive Officer, National Marrow Donor Program; Brian Wallach & Sandra Abrevaya, Co-Founders, I AM ALS; and, Rene Quashie, JD, Vice President, Digital Health, Consumer Technology Association. On April 21, 2026, the Subcommittee on Health held a hearing related to H.R. 5150. The title of the hearing was ``The Fiscal Year 2027 Department of Health and Human Services Budget.'' The Subcommittee received testimony from: The Honorable Robert F. Kennedy, Jr., Secretary, U.S. Department of Health and Human Services. Committee Cost Estimate Pursuant to clause 3(d)(1) of rule XIII, the Committee adopts as its own the cost estimate prepared by the Director of the Congressional Budget Office pursuant to section 402 of the Congressional Budget Act of 1974. At the time this report was filed, the estimate was not available. Earmark, Limited Tax Benefits, and Limited Tariff Benefits Pursuant to clause 9(e), 9(f), and 9(g) of rule XXI, the Committee finds that H.R. 5160 contains no earmarks, limited tax benefits, or limited tariff benefits. Advisory Committee Statement No advisory committees within the meaning of section 5(b) of the Federal Advisory Committee Act were created by this legislation. Applicability to Legislative Branch The Committee finds that the legislation does not relate to the terms and conditions of employment or access to public services or accommodations within the meaning of section 102(b)(3) of the Congressional Accountability Act. Section-by-Section Analysis of the Legislation Section 1. Short title Section 1 provides a short title of ``Stem Cell Therapeutic and Research Reauthorization Act of 2025''. Section 2. Reauthorization of the C.W. Bill Young Cell Transplantation Program Section 2 reauthorizes the C.W. Bill Young Cell Transplantation Program through Fiscal Year 2031. Section 3. Cord blood inventory Section 3 reauthorizes appropriations for the collection and maintenance of the National Cord Blood Inventory. This section also updates inventory management parameters to facilitate maximizing the availability of high-quality cord blood units that meet applicable clinical and quality standards. Changes in Existing Law Made by the Bill, as Reported In compliance with clause 3(e) of rule XIII of the Rules of the House of Representatives, changes in existing law made by the bill, as reported, are shown as follows (existing law proposed to be omitted is enclosed in black brackets, new matter is printed in italics, and existing law in which no change is proposed is shown in roman): PUBLIC HEALTH SERVICE ACT * * * * * * * TITLE III--GENERAL POWERS AND DUTIES OF PUBLIC HEALTH SERVICE * * * * * * * PART I--C.W. BILL YOUNG CELL TRANSPLANTATION PROGRAM * * * * * * * SEC. 379B. AUTHORIZATION OF APPROPRIATIONS. For the purpose of carrying out this part, there are authorized to be [appropriated $31,009,000] appropriated-- (1) $31,009,000 for each of fiscal years 2022 through 2026[.]; and (2) $33,009,000 for each of fiscal years 2027 through 2031. * * * * * * * ---------- STEM CELL THERAPEUTIC AND RESEARCH ACT OF 2005 * * * * * * * SEC. 2. CORD BLOOD INVENTORY. (a) In general.--The Secretary of Health and Human Services shall enter into contracts with qualified cord blood banks to assist in the collection and maintenance of the inventory goal of [at least 150,000 new units of high-quality cord blood] a sufficient supply, as determined by the Secretary, of high- quality cord blood units to be made available for transplantation through the C.W. Bill Young Cell Transplantation Program and to carry out the requirements of subsection (b). (b) Requirements.--The Secretary shall require each recipient of a contract under this section-- (1) to acquire, tissue-type, test, cryopreserve, and store donated units of cord blood acquired with the informed consent of the donor, as determined by the Secretary pursuant to section 379(c) of the Public Health Service Act, in a manner that complies with applicable Federal and State regulations; (2) to encourage donation from a genetically diverse population; (3) to make cord blood units that are collected pursuant to this section or otherwise and meet all applicable Federal standards available to transplant centers for transplantation; (4) to make cord blood units that are collected, but not appropriate for clinical use, available for peer- reviewed research; (5) to make data available, as required by the Secretary and consistent with section 379(d)(3) of the Public Health Service Act (42 U.S.C. 274k(d)(3)), as amended by this Act, in a standardized electronic format, as determined by the Secretary, for the C.W. Bill Young Cell Transplantation Program; and (6) to submit data in a standardized electronic format for inclusion in the stem cell therapeutic outcomes database maintained under section 379A of the Public Health Service Act, as amended by this Act. (c) Application.--To seek to enter into a contract under this section, a qualified cord blood bank shall submit an application to the Secretary at such time, in such manner, and containing such information as the Secretary may reasonably require. At a minimum, an application for a contract under this section shall include a requirement that the applicant-- (1) will participate in the C.W. Bill Young Cell Transplantation Program for a period of at least 10 years beginning on the last date on which the recipient of a contract under this section receives Federal funds under this section; (2) will make cord blood units collected pursuant to this section available through the C.W. Bill Young Cell Transplantation Program [in perpetuity or] for such time as determined viable by the Secretary; (3) will provide a plan to increase cord blood unit collections at collection sites that exist at the time of application, assist with the establishment of new collection sites, or contract with new collection sites; (4) will annually provide to the Secretary a plan for, and demonstrate, ongoing measurable progress toward achieving self-sufficiency of cord blood unit collection and banking operations; and [(5) if the Secretary determines through an assessment, or through petition by the applicant, that a cord blood bank is no longer operational or does not meet the requirements of section 379(d)(4) of the Public Health Service Act (as added by this Act) and as a result may not distribute the units, transfer the units collected pursuant to this section to another qualified cord blood bank approved by the Secretary to ensure continued availability of cord blood units.] (5) if the Secretary determines through an assessment, or through petition by the applicant, that a cord blood bank is no longer operational, does not meet the requirements described in subsection (d)(4), or does not meet the requirements of section 379(d)(4) of the Public Health Service Act, and as a result may not distribute the high-quality units, the Secretary may transfer the units collected pursuant to this section to another qualified cord blood bank or entity approved by the Secretary to ensure continued availability of high-quality cord blood units. (d) Duration of Contracts.-- (1) In general.--Except as provided in paragraph (2), the term of each contract entered into by the Secretary under this section shall be for a period of at least 10 years beginning on the last date on which the recipient of a contract under this section receives Federal funds under this section. The Secretary shall ensure that no Federal funds shall be obligated under any such contract after the date that is 5 years after the date on which the contract is entered into, except as provided in paragraphs (2), (3), and (4). (2) Extensions.--The Secretary may extend the period of funding under a contract under this section to exceed a period of 5 years if-- (A) the Secretary finds that the inventory goal described in subsection (a) has not yet been met; (B) the Secretary does not receive an application for a contract under this section meeting the requirements under subsection (c) from any qualified cord blood bank that has not previously entered into a contract under this section; or (C) the Secretary determines that the outstanding inventory need cannot be met by the qualified cord blood banks under contract under this section. (3) Extension eligibility.--A qualified cord blood bank shall be eligible for a 5-year extension of a contract awarded under this section, as described in paragraph (2), provided that the qualified cord blood bank-- (A) demonstrates a superior ability to satisfy the requirements described in subsection (b) and achieves the overall goals for which the contract was awarded; (B) provides a plan for how the qualified cord blood bank will increase cord blood unit collections at collection sites that exist at the time of consideration for such extension of a contract, assist with the establishment of new collection sites, or contract with new collection sites; and (C) annually provides to the Secretary a plan for, and demonstrates, ongoing measurable progress toward achieving self-sufficiency of cord blood unit collection and banking operations. [(4) Consideration of best science.--The Secretary shall take into consideration the best scientific information available in order to maximize the number of cord blood units available for transplant when entering into contracts under this section, or when extending a period of funding under such a contract under paragraph (2).] (4) Consideration of best science.--The Secretary shall take into consideration current scientific and clinical information in order to maximize the availability of high-quality cord blood units meeting applicable clinical and quality standards for transplant when entering into contracts under this section, or when extending a period of funding under such a contract under paragraph (2). (5) Consideration of banked units of cord blood.--In extending contracts pursuant to paragraph (3), and determining new allocation amounts for the next contract period or contract extension for such cord blood bank, the Secretary shall take into account the number of cord blood units banked in the National Cord Blood Inventory by a cord blood bank during the previous contract period, in addition to consideration of the ability of such cord blood bank to increase the collection and maintenance of additional, genetically diverse cord blood units. (e) Inventory Management.-- (1) In general.--The Secretary shall manage the size and composition of the National Cord Blood Inventory to maximize clinical utility, ensure genetic diversity, and promote the efficient use of resources. (2) Considerations.--In carrying out paragraph (1), the Secretary may-- (A) on the Secretary's own initiative or upon petition by a qualified cord blood bank, make determinations regarding the continued storage of cord blood units based on the best available scientific and clinical evidence; or (B) prioritize the collection, retention, or disposition of cord blood units based on scientific, clinical, or operational considerations that the Secretary determines to be relevant. [(e)] (f) Regulations.--The Secretary may promulgate regulations to carry out this section. [(f)] (g) Definitions.--In this section: (1) The term ``C.W. Bill Young Cell Transplantation Program'' means the C.W. Bill Young Cell Transplantation Program under section 379 of the Public Health Service Act, as amended by this Act. (2) The term ``cord blood donor'' means a mother who has delivered a baby and consents to donate the neonatal blood remaining in the placenta and umbilical cord after separation from the newborn baby. (3) The term ``cord blood unit'' means the neonatal blood collected from the placenta and umbilical cord of a single newborn baby. (4) The term ``high quality cord blood unit'' means a cord blood unit that meets current industry standards and any requirements of the Food and Drug Administration. [(4)] (5) The term ``qualified cord blood bank'' has the meaning given to that term in section 379(d)(4) of the Public Health Service Act, as amended by this Act. [(5)] (6) The term ``Secretary'' means the Secretary of Health and Human Services. [(g)] (h) Authorization of Appropriations.--To carry out this section, there is authorized to be appropriated $23,000,000 for each of [fiscal years 2022 through 2026] fiscal years 2027 through 2031. * * * * * * * [all]

Source: https://api.congress.gov/v3/committee-report/119/hrpt/724